AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰 Latest breakthroughs
🗺️ Disease Atlas · Reproductive system or breast disease

endometrial cancer

Primary or metastatic malignant neoplasm involving the endometrium (mucous membrane that lines the endometrial cavity).

🔔 Follow weekly
🧬12770genes / proteins with evidence
💊242drugs and clinical candidates
🧪12+recruiting trials worldwide
✅2approved
📈39phase 3
🧬

Understand endometrial cancer

Cancer · Cells that grow out of control
🎓 Learn more

What it is

Uterine cancer is a cancer that forms in tissues of the uterus, which is sometimes called the womb. The uterus is the place where a fetus grows during pregnancy.

There are two types of uterine cancer:

Endometrial cancer is the most common type. This type of cancer begins in the cells lining the uterus, known as the endometrium.

From MedlinePlus: Uterine Cancer (US National Library of Medicine) ↗

🧬 Cancer: Cancer is a group of diseases in which some of the body's cells grow and divide without control, and can spread to other parts of the body.

❓ Why it happens

  • Changes (mutations) build up in the genes that tell a cell when to grow, divide and die.
  • Most of these changes happen during life: tobacco, too much sun, alcohol, some infections (such as HPV and hepatitis B and C), radiation, obesity and ageing all raise the risk.
  • Some people inherit a faulty gene that raises their risk, such as BRCA1 or BRCA2.

🫀 What it does to the body

  • Cancer cells form a lump (tumour) that can press on or invade nearby organs.
  • They can travel through the blood or lymph to start new tumours elsewhere (metastasis).
  • Blood cancers crowd out healthy blood cells in the bone marrow.

🧱 Why it is hard to cure

  • Every cancer is different, even between two people with the same type - and inside one tumour.
  • Cancer cells keep changing, so they can learn to resist a medicine that worked at first.
  • Cancer cells are the body's own cells, so killing them without harming healthy cells is hard.
  • Many cancers cause no symptoms until they have spread, and a new medicine often takes more than ten years to go from the lab to patients.

🚀 What research is trying now

  • Targeted medicines against the exact gene change in a tumour (for example EGFR, ALK or KRAS).
  • Immunotherapy that helps the immune system recognise cancer, including CAR-T cell therapy.
  • Personalised cancer vaccines built from each tumour's mutations, now in late trials.
  • Blood tests that look for tumour DNA to find cancer earlier, and AI to read scans and slides.

General information about cancer, reviewed by people; it does not describe any one person. Below: the evidence for endometrial cancer itself.

🤖

AI briefing

Where the science on endometrial cancer stands, from the evidence on this page

AI reads the targets, drugs, trials and papers below and writes where the science stands — every claim cited. It is shared with everyone who opens endometrial cancer.

🎯

Top targets

Genes and proteins ranked by Open Targets evidence (0-1)
MSH6 mutS homolog 6PROTACsmall molecule🧊 AlphaFold structure ↗ 0.87
PTEN phosphatase and tensin homologPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.83
FBXO11 F-box protein 11PROTAC🧊 AlphaFold structure ↗ 0.74
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alphaPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.74
MSH2 mutS homolog 2PROTACsmall molecule🧊 AlphaFold structure ↗ 0.74
FGFR2 fibroblast growth factor receptor 2PROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.72
ARID1A AT-rich interaction domain 1APROTAC🧊 AlphaFold structure ↗ 0.72
CDH1 cadherin 1PROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.71
PIK3R1 phosphoinositide-3-kinase regulatory subunit 1PROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.71
TP53 tumor protein p53PROTACothersmall molecule🧊 AlphaFold structure ↗ 0.71
MSH3 mutS homolog 3PROTACsmall molecule🧊 AlphaFold structure ↗ 0.70
MLH1 mutL homolog 1PROTACsmall molecule🧊 AlphaFold structure ↗ 0.69
KRAS KRas proto-oncogene, GTPasePROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.68
PPP2R1A protein phosphatase 2 scaffold subunit AalphaPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.68
FBXW7 F-box and WD repeat domain containing 7PROTACsmall molecule🧊 AlphaFold structure ↗ 0.67

Green labels: what the target is known to be druggable by. The score combines genetics, somatic mutations, drugs, expression and literature.

💊

Drugs and candidates

Every medicine linked to endometrial cancer, by how far it has got
Approved · 2
DostarlimabProgrammed cell death protein 1 antagonistApproved
Doxorubicin HydrochlorideDNA topoisomerase II alpha inhibitorApproved
In phase 2 / 3 · 20
AtezolizumabProgrammed cell death 1 ligand 1 inhibitorPhase 3
BenmelstobartPhase 3
BevacizumabVascular endothelial growth factor A inhibitorPhase 3
CarboplatinPhase 3
Catequentinib HydrochloridePhase 3
CisplatinPhase 3
Show all 20
DoxorubicinDNA topoisomerase II alpha inhibitorPhase 3
DurvalumabProgrammed cell death 1 ligand 1 inhibitorPhase 3
DydrogesteroneProgesterone receptor agonistPhase 3
Epirubicin HydrochloridePhase 3
FilgrastimGranulocyte colony stimulating factor receptor agonistPhase 3
FruquintinibVascular endothelial growth factor receptor inhibitorPhase 3
IxabepiloneTubulin inhibitorPhase 3
LenvatinibVascular endothelial growth factor receptor inhibitorPhase 3
Medroxyprogesterone AcetateProgesterone receptor agonistPhase 3
Megestrol AcetateProgesterone receptor agonistPhase 3
MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor; Mitochondrial glycerol-3-phosphat…Phase 3
MorphineMu opioid receptor agonistPhase 3
NiraparibPoly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitorPhase 3
OlaparibPARP 1, 2 and 3 inhibitorPhase 3
Early trials · 20
Bmx-001Phase 1/2
Com-701Phase 1/2
Cyc-065Phase 1/2
Denileukin DiftitoxElongation factor 2 inhibitor; Interleukin-2 receptor binding agentPhase 1/2
Farletuzumab EcteribulinPhase 1/2
IbrilatazarPhase 1/2
Show all 20
Ifinatamab DeruxtecanPhase 1/2
Lutetium Lu 177 Zadavotide GuraxetanPhase 1/2
Lutetium Lu-177 Vipivotide TetraxetanGlutamate carboxypeptidase II binding agentPhase 1/2
Lutetium Lu177 EdotreotidePhase 1/2
Lutetium Oxodotreotide Lu-177Somatostatin receptor binding agentPhase 1/2
Luveltamab TazevibulinPhase 1/2
MolgramostimPhase 1/2
NarazaciclibPhase 1/2
Nogapendekin AlfaPhase 1/2
Pasifolate ExatecanPhase 1/2
PemetrexedThymidylate synthase inhibitor; Dihydrofolate reductase inhibitorPhase 1/2
RegramostimGranulocyte colony stimulating factor receptor agonistPhase 1/2
RenvistobartPhase 1/2
SargramostimGranulocyte-macrophage colony-stimulating factor receptor agonistPhase 1/2
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy